Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.50 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.50 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930881 | 0.89 | POLB (0.62) | AKR1C3HDAC6POLBHDAC11HDAC3 | |
| SCHEMBL2931563 | 0.86 | POLB (0.69) | AKR1C3HDAC6POLBHDAC3HDAC1 | |
| SCHEMBL3766427 | 0.80 | AKR1C3 (1.00) | AKR1C3HDAC6POLBMTORHDAC11 | |
| SCHEMBL2934474 | 0.79 | AKR1C3 (0.54) | AKR1C3HDAC6POLBNR4A2PIK3CA | |
| SCHEMBL2929642 | 0.79 | TDP1 (0.53) | AKR1C3HDAC6POLBNR4A2PIK3CA | |
| SCHEMBL2931483 | 0.79 | POLB (0.85) | AKR1C3HDAC6POLBMTORPIK3CA | |
| SCHEMBL2933099 | 0.78 | HSP90AA1 (0.52) | AKR1C3HDAC6POLBHDAC11NR4A2 | |
| SCHEMBL3120847 | 0.78 | POLB (0.55) | AKR1C3HDAC6POLBHDAC11NR4A2 | |
| SCHEMBL1965467 | 0.78 | POLB (0.60) | AKR1C3HDAC6POLBNR4A2PIK3CA | |
| SCHEMBL2929452 | 0.77 | AKR1C3 (0.71) | AKR1C3HDAC6POLBHDAC11HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377983-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-7820821-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | VTVX HOLDINGS I LLC | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | AURKC, AURKA, AURKB | AKR1C3 944/4885HDAC6 251/4885POLB 1990/4885 |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | AURKC, AURKA, AURKB | AKR1C3 944/4885HDAC6 251/4885POLB 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.